RAPGEF6

Across TCGA pan-cancer cohorts, RAPGEF6 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RAPGEF6 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RAPGEF6 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RAPGEF6 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD and HNSC are the cancer types where RAPGEF6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	II,III,IV	0.451	0.893	.044	2	view →
HNSC	OS	Tertile	III,IV	0.892	0.520	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RAPGEF6–LUAD (OS)

Open the LUAD breakdown →